⌕
Immunome · IMNM · Nasdaq
Tenet 49 · Mixed
Compare
$17.18−2.44%At closeTenet 49 · Mixed
$17.18−0.43 (−2.44%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Immunome (IMNM) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is IMNM's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Seeking AlphaNov 17, 2026 · 10:12 ET
Immunome: De-Risked With The FDA, With An Admirably Deep Clinical Bench

I maintain a Buy on Immunome, Inc.: its $2.1 billion market cap leaves upside versus the Springworks acquisition valuation. Varegacestat's phase 3 progression-free survival hazard ratio was 0.16; the FDA decision is due …

IMNM −2.4% todayRead at source ↗
● BenzingaNov 10, 2026 · 10:22 ET
Immunome Analysts Cut Their Forecasts After Q3 Results

Immunome Inc (NASDAQ:IMNM) on Monday posted a wider-than-expected loss for the third quarter.…

IMNM −2.4% todayRead at source ↗
● Business WireNov 9, 2026 · 16:02 ETCOMPANY'S OWN WORDS
Immunome Reports Third Quarter 2026 Financial Results and Provides Business Update

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class cancer therapies, today announced financial results for …

IMNM −2.4% todayRead at source ↗
● Business WireNov 6, 2026 · 16:00 ETCOMPANY'S OWN WORDS
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a clinical-stage targeted oncology company focused on developing first-in-class and best-in-class cancer therapies, announced today that on …

IMNM −2.4% todayRead at source ↗
● Zacks Investment ResearchNov 4, 2026 · 10:55 ET
Wall Street Analysts Predict a 73.95% Upside in Immunome (IMNM): Here's What You Should Know

The consensus price target hints at a 74% upside potential for Immunome (IMNM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean …

IMNM −2.4% todayRead at source ↗
● Zacks Investment ResearchNov 4, 2026 · 10:41 ET
4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates

Four biotech stocks, including TG Therapeutics and Immunome, show positive Earnings ESPs and favorable Zacks Ranks, positioning them for potential third-quarter earnings beats.…

IMNM −2.4% todayRead at source ↗
● Business WireNov 2, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Immunome to Present at Guggenheim 3rd Annual Healthcare Innovation Conference

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that its mana…

IMNM −2.4% todayRead at source ↗
● Business WireOct 30, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Immunome Announces EMA Validation of Marketing Authorization Application for Varegacestat for the Treatment of Adults with Desmoid Tumors

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the Euro…

IMNM −2.4% todayRead at source ↗
● Business WireOct 26, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Immunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the presentat…

IMNM −2.4% todayRead at source ↗
● Business WireOct 6, 2026 · 16:02 ETCOMPANY'S OWN WORDS
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a clinical-stage target oncology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today t…

IMNM −2.4% todayRead at source ↗
● Business WireSep 30, 2026 · 07:45 ETCOMPANY'S OWN WORDS
Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the U.S.…

IMNM −2.4% todayRead at source ↗
● Business WireSep 8, 2026 · 16:02 ETCOMPANY'S OWN WORDS
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a clinical-stage target oncology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today t…

IMNM −2.4% todayRead at source ↗
● Business WireSep 2, 2026 · 07:45 ETCOMPANY'S OWN WORDS
Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome m…

IMNM −2.4% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

NVDA29−0.4%
WDAY4−5.8%
BBW3−2.6%

Article counts from the last market-wide feed page, across every symbol we track and not just IMNM · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.